August 19, 2025, Suzhou, China - The new drug application (NDA) for Mometasone Furoate Nasal Spray, an independently developed product by CF PharmTech, has been officially accepted by the National Medical Products Administration (NMPA). The product is available in two specifications: 50μg per spray, 60 sprays per bottle; and 50μg per spray, 140 sprays per bottle. It is indicated for the treatment of seasonal or perennial allergic rhinitis in adults, adolescents, and children aged 3 years and above.

Mometasone Furoate Nasal Spray
Applicable to adults, adolescents, and children aged 3 years and above

In recent years, China has incorporated chronic disease prevention and control into policy documents such as the "Healthy China 2030" Planning Outline. As a key component of chronic diseases, allergic diseases have seen a steady rise in incidence and become a major issue affecting residents' health. In 2024, the number of patients with allergic rhinitis in China was approximately 245.5 million, and this figure is expected to increase to 269.6 million by 2033 [1].

As a high-efficiency local anti-inflammatory inhaled corticosteroid (ICS), Mometasone Furoate Nasal Spray boasts advantages including strong anti-inflammatory effects, low systemic bioavailability, and good safety. It is recommended as a first-line medication for allergic rhinitis in both domestic and international guidelines. The two specifications of the product applied for this time can provide patients with more flexible medication options.

CF PharmTech

Creating a Full-Age Solution for Allergic Rhinitis

Nasal spray preparations enable precise targeted drug delivery and are widely used in otorhinolaryngology, respiratory medicine, and pediatrics. The company has built a diverse product portfolio:

Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (Shufeimin®), the first of its kind launched in China, has effectively filled the gap in the treatment of allergic rhinitis and was included in the National Reimbursement Drug List (NRDL) in 2023：

Mometasone Furoate Nasal Spray covers populations aged 3 years and above, while Budesonide Nasal Spray covers those aged 6 years and above. Together, they can meet the needs of both seasonal acute attacks and perennial maintenance treatment.

Relying on its independent nasal spray R&D platform, CF PharmTech develops products in strict accordance with FDA guidelines and domestic regulations. It continuously improves its layout in the field of allergic rhinitis treatment and is committed to providing patients with more high-quality treatment options.

References

[1] Analysis by Frost & Sullivan